NEW YORK--(BUSINESS WIRE)--Embleema, the leader in blockchain for health, announced today that it has entered into a partnership with Pharmagest Interactive, a leading pharmacy software group in Europe, to allow patients to directly download their health data from pharmacies and health centers, placing patients at the center of care. Patients will gain individual access to opt in to advanced clinical research using Blockchain technology to guarantee the control, integrity and traceability of health data.
The strategic partnership will accelerate the joint development of blockchain-based applications for patients and pharmacies, and further Embleema’s commercial deployment across Pharmagest’s extensive network of over 10,000 pharmacies in Europe. The partnership will also enable Pharmagest to scale the adoption of its services among patients that are already digitizing their prescription data through its current pharmacy client network.
In July 2018, Embleema launched PatientTruth in the US, the first blockchain-based personal health record system, which lets patients assemble their health history from dispersed health records, enabling full control over their healthcare data sharing. Patients receive tokens in exchange for their active participation in clinical research. Embleema was the first company to offer practical means for patients to own their digital health assets, providing both control and monetization without third party data brokers.
Blockchain allows patients to own their data on a decentralized marketplace, as all transactions are registered on distributed ledgers, removing the need for a third party to authenticate movements. Patients have access to the full audit trail of their healthcare data and receive automated payments through smart contracts.
The strategic partnership with Pharmagest will enable Embleema to accelerate the development of its decentralized health data marketplace, a service for patients to connect with researchers to share and collect relevant health data, and accelerate drug development. Pharmagest will be a leading partner in Europe, offering patients within its network an opportunity to opt in to research.
Thierry Chapusot, CEO of Pharmagest said: "We believe in the enormous potential of blockchain technology in the healthcare sector which is destined to become a key technology for protecting data and ensuring transparency for the patient. The system developed by Embleema is at the forefront of decentralizing and sharing data to better monitor the efficacy and safety of drugs. With a world-class team, Embleema has already demonstrated its potential with a solution which works and generated interest by key partners in the pharmaceutical industry as a means to shorten time to market for innovative drugs. We are very excited about the opportunity to participate in its deployment and eager to create complementary synergies with our Group.”
Robert Chu, CEO of Embleema added: "We are delighted by this strategic partnership with Pharmagest Group which will enable us to integrate our blockchain technology within the different solutions already developed by a Group that has been at the cutting edge of innovation in Europe for the last 25 years. Pharmagest's addition to our shareholder base will give us the financial resources needed for the rapid deployment of these technologies for patients through pharmacies or medical establishments equipped by Pharmagest. Through the deployment of this blockchain technology on a large scale basis for the benefit of patients, not only in the United-States, but now also in Europe."
About Pharmagest Group
Pharmagest Group is the French pharmacy information technology leader, with a market share of more than 42% and more than 1,000 employees. The Group's strategy is based on a core business of improving healthcare through information technology innovation and developing two priority areas: 1/ Services and technologies for healthcare professionals, with a focus on assisting pharmacies in the area of patient medication compliance; and 2/ technologies for improving the efficacy of healthcare systems. This strategy is executed through specialised business lines developed by Pharmagest Group: pharmacy IT solutions, e-Health solutions, solutions for healthcare professionals, solutions for pharmaceutical laboratories, connected health devices and apps, and a sales financing marketplace.
These businesses are divided into four divisions: Pharmacy - Europe Solutions, Health and Social Care Facilities Solutions, e-Health Solutions and FinTech.
Embleema is the patient-driven healthcare blockchain network for secure sharing of personal health records. Hosted on a private Ethereum blockchain, Embleema’s consolidated, highly-secure repository provides the healthcare ecosystem with an undisputed and holistic view of patients’ medical history, Embleema is creating a decentralized healthcare data economy by connecting the key stakeholders in the healthcare industry, directly with patients while maintaining the patient’s data sovereignty.
CEO Robert Chu left his role as Senior Vice President, Global Technology Solutions at IMS Health to found Embleema in June 2017 and is supported by a team of healthcare and technology executives from Harvard Medical School, T-Systems, the Pharmaceuticals Division of Pierre Fabre and iBionext and Nokia / Withings Digital Health.
Representational image of Bitcoin. (File: Bloomberg) By Nathaniel Popper Hamas, the militant Palestinian group, has been designated a terrorist organization… Read More
Just yesterday we told you how there was a new Faketoshi in town, staking a questionable claim to the Bitcoin… Read More
Share Tweet Send Share Bitcoin price predictions have been coming thick and fast in recent months as the world’s top… Read More
For a man that wants nothing to do with Bitcoin , economist and Euro Pacific Capital CEO Peter Schiff never… Read More
Casa, a crypto firm that provides a private key management service and Bitcoin node machine, has unveiled a node monitor… Read More
Ethereum Classic vs Ethereum: Classic is making a comeback today An important price level has been broken 0.037673 looks to… Read More